Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page : W+ d# u7 U0 u3 T/ \- j! [
$ h6 q: s1 F5 u5 M7 W' k
1 S3 [* @ z! b3 K; ^Sub-category:: Q% V b6 T2 _8 ]4 x6 \9 }6 g3 s
Molecular Targets 4 C5 a' y; i! }" u
" O% {, ^& Y4 U# i0 q( n7 ?6 ~, V7 \
- l" ~" e" ^! Q5 X0 `2 q9 ZCategory:: O9 v/ {( x! z5 R' L6 [: X l
Tumor Biology
& P+ k: \ m$ r4 j1 ^, J" R( w3 F7 s" @7 B
4 w2 O2 w1 [! r" O2 U) x, tMeeting:
" s; b# N& {0 {3 W" E2011 ASCO Annual Meeting 2 n6 k ~% @) n, h) ?: q
- B* D5 l5 s! V$ _, U3 R' p9 r2 j
# w, n" {5 Y, [Session Type and Session Title:, X/ O# S; N" E8 H
Poster Discussion Session, Tumor Biology
6 `( F3 n! p* O+ v! t
6 c7 C1 K- C6 K! h6 Z9 Z- o3 X4 p
$ J9 z4 H8 _; {8 Y) w' nAbstract No:
- o$ o( T. y/ h( y1 V: {: U% x' h- |10517
1 `- W/ G4 X: V9 T; u
8 L4 w8 s0 V8 b3 `
i5 j( \5 j1 o9 _6 iCitation:% r; ?* s* U# y! o. m* h
J Clin Oncol 29: 2011 (suppl; abstr 10517) 6 E2 F9 c1 d' W- m" L6 o# P2 L
0 j& E2 T$ S4 H: p# ]2 q
# z( O5 A) T, O- }6 q
Author(s):
* S/ `% ?# U" J% E/ PJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ) V& E, t, ~( H5 k; H$ |' O4 _7 p
! K, _* ^8 C2 j E
" |' Y5 a4 |' h3 |. U
/ M4 `' x; G1 I9 h3 |Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings., k7 v4 L8 S$ k0 ?/ f
' z* T% p3 u# T5 J4 T; m8 XAbstract Disclosures& ]8 R! M* { O9 B- {2 q
5 F9 t8 p8 C( @0 I
Abstract:9 j0 `( o/ M. w! D4 r6 D+ l
0 E' _- p) r& T: H
, m/ m9 \' s- l" MBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.* m) g" X# F6 q8 R0 |7 r) T
9 H; \: Y' n" s' ?0 {; X' G7 `
# p. p# Y; p) p
|